Oral Alpan, MD
Allergy & Immunology · Springfield, VANPI 1881788610
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Pharming Healthcare, Inc. at 33.0% of the total. Reporting peaked in 2019 at $27,001 and has fallen 88.2% since, to $3,173 in 2025. Among allergy & immunology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $172.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$29K
- Shire North American Group Inc$17K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Genentech USA, Inc.$10K
- BD$9K
- AstraZeneca$1K
- plus $6K from 21 others
Across 58 payments — averaging $2044.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ADMA Biomanufacturing LLC$52K
- Shire North American Group Inc$23K
- Sanofi US Services Inc.$12K
- Grifols Biologicals LLC$11K
- Grifols Therapeutics LLC$7K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- plus $11K from 4 others
What the payments were for
- Consulting fees$25,91030%
- Speaking & faculty fees$44,44651%
- Travel & lodging$4,7915%
- Food & beverage$12,54914%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 60 | $28,968 |
| Shire North American Group Inc | 30 | $17,160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $15,157 |
| Genentech USA, Inc. | 59 | $10,214 |
| BD | 4 | $8,783 |
| AstraZeneca | 41 | $1,230 |
| Sanofi | 53 | $1,228 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,085 |
| Pfizer | 30 | $657 |
| CSL Behring | 18 | $616 |
| Grifols USA, LLC | 24 | $580 |
| GSK | 17 | $359 |
| Novartis | 15 | $333 |
| Amgen(2 entities) | 11 | $308 |
| Bio Products Laboratory USA, Inc. | 12 | $259 |
| ADMA Biomanufacturing LLC | 8 | $210 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $200 |
| Kaleo, Inc. | 8 | $150 |
| Kedrion Biopharma, Inc. | 3 | $57 |
| Ionis Pharmaceuticals, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $42 |
| Blueprint Medicines Corporation | 1 | $32 |
| Tersera Therapeutics LLC | 1 | $29 |
| LEO Pharma Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,767 in reported general payments places this provider in the 90th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 116 | $566,898 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 42 | $203,657 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 19 | $132,944 |
| XolairOmalizumab | 24 | $85,153 |
| Cromolyn Sodium | 19 | $19,299 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,473 |
| Epinephrine | 14 | $3,223 |
| Promethazine Hcl | 29 | $2,645 |
| Diphenhydramine Hcl | 47 | $1,849 |
| Sodium Chloride0.9 % Sodium Chloride | 42 | $1,193 |
| Solu-CortefHydrocortisone Sodium Succ/Pf | 27 | $1,145 |
| Ondansetron HclOndansetron Hcl/Pf | 28 | $633 |
| Azithromycin | 22 | $189 |
| Prednisone | 35 | $101 |
| FamotidineFamotidine/Pf | 27 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Cuvitru | $15,157 | $699,842135 claims |
| Grifols USA, LLCGamunex-C | $580 | $203,65742 claims |
| GSKBreo Ellipta | $359 | $4,47311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Springfield
- Satyen GadaSpringfield$19K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
- Ananth ThyagarajanBurke$97K
- Larry BorishCharlottesville$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.